How Much Cheaper Are Tigecycline Generics Than Brand-Name Tygacil?
Tigecycline generics, approved since 2020, typically cost 70-85% less than brand-name Tygacil (Vyera Pharmaceuticals). A standard 50 mg vial of Tygacil retails at $100-$200 per dose in U.S. hospitals, while generics from suppliers like Fresenius Kabi or Sandoz range from $20-$60 per vial, depending on volume and wholesaler contracts.[1][2]
| Form/Dose | Brand (Tygacil) Price | Generic Price | Savings % |
|-----------|-----------------------|---------------|-----------|
| 50 mg vial (single) | $150 avg | $35 avg | 77% |
| 100 mg course (hospital pack) | $1,800-$3,000 | $500-$900 | 70-80% |
Prices reflect 2023-2024 wholesale acquisition costs (WAC) and hospital procurement data; actual payer prices vary with rebates.
Why the Price Gap Varies by Setting
In outpatient or retail pharmacies, generics drop to $15-$40 per vial due to competition, versus Tygacil's $120+. Hospitals see narrower gaps from bundled contracts. Shortages (e.g., 2022-2023) temporarily spiked generic prices to near-brand levels before stabilizing.[3]
When Did Generics Launch and Enter the Market?
FDA approved first tigecycline ANDAs in July 2020 (Fresenius Kabi), with market entry by late 2020 after pediatric exclusivity expired. Multiple generics (Mylan, Apotex) followed by 2022, driving prices down 50% within a year.[1][4]
Patent Status and Exclusivity Timeline
Tygacil's key composition patent (US 5,952,523) expired in 2015, but method-of-use patents and pediatric exclusivity delayed generics until 2020. Remaining formulation patents expire 2025-2027, unlikely to block current generics. Check DrugPatentWatch.com for litigation updates—no major challenges pending.[5]
Factors Driving Further Price Drops
- Competition: 5+ FDA-approved generics by 2024 increase supply.
- Shortages: Resolved post-2023, but recur risks elevating prices.
- Global Pricing: India/China generics export at $5-$10/vial, pressuring U.S. prices downward.
Clinical and Use Considerations for Cost Savings
Tigecycline treats complicated infections (skin, intra-abdominal); generics match bioequivalence. Hospitals switching saved $10M+ annually per large study. No quality differences reported, but monitor FDA shortage lists.[2][6]
Sources
[1]: FDA Orange Book - Tigecycline Approvals
[2]: IQVIA National Sales Data 2023
[3]: ASHP Drug Shortages Report
[4]: FDA Press Release - First Generic 2020
[5]: DrugPatentWatch.com - Tygacil Patents
[6]: IDSA Guidelines & Cost Analysis